Centene (CNC) is higher in Wednesday trading as investors continue to position around the company’s improved profitability trajectory following its Q1 2026 report and increased 2026 guidance. The latest leg up appears tied to follow-through buying after the earnings-driven re-rating, rather than a single new contract or regulatory headline hitting today.

In its April 28, 2026 Form 8-K earnings release, Centene reported Q1 2026 results that materially exceeded expectations and raised its 2026 outlook, including higher premium and service revenue guidance of $171.0–$175.0 billion and higher floors for GAAP diluted EPS (> $2.37) and adjusted diluted EPS (> $3.40). That guidance lift reinforced a narrative that medical-cost management is improving versus 2025, supporting a stronger earnings power profile for 2026.

With the stock now reacting positively to the improved outlook, the next catalysts are whether Centene can sustain health benefit ratio progress through 2026 and whether membership and rate dynamics in Medicaid and Marketplace remain supportive. Investors will also watch for any incremental state contracting updates and further commentary on cost controls in subsequent company updates and filings.